The Lyme Treatment Foundation is an all-volunteer non-profit organization that provides medical treatment grants to people of all ages in the United States, Canada and parts of Europe (the UK and Germany) to fund diagnostic testing and treatment of Lyme disease and the associated tick-borne illnesses.
We provide grants worth up to $4,000 to those in need to help pay for blood tests and long-term treatment of Lyme disease and other tick-borne illnesses.
We also award research grants to researchers at universities studying tick-borne diseases around the world. Our first funded research study titled, New pharmacological agents to treat persistent infections is underway at the University of Oxford.
Lyme disease and the associated tick-borne illnesses can be devastating both physically and financially and our goal is to help those who are suffering get an accurate blood test, so that they may receive a proper diagnosis and appropriate treatment from a Lyme disease specialist.
Testing for Lyme disease is not 100% accurate, and many with Lyme disease do not test positive with the typical blood tests given in a doctor’s office. Without a positive blood test, doctors are unable to treat these patients. Many suffer for years before being referred to a Lyme disease specialist for private testing and treatment.
While these private labs are accurate, they are also very costly and many cannot afford to get a proper diagnosis and appropriate treatment on their own.
Our goal at the Lyme Treatment Foundation is to fund diagnostic testing and treatment for as many as possible, so that those suffering from Lyme disease and the other tick-borne illnesses may go on to live healthy, happy and fulfilling lives.
Please consider making a donation! Many are in need of life saving treatment. Many more are unable to work, raise their families, or go to school because of this debilitating disease and they all need our help!
Thank you for your generosity and support! Let's achieve our goal of Lyme treatment for all!
Lyme Treatment Foundation, Inc. 2024